Here are four insights:
1. K2M has positioned itself as a strong competitor in the complex spinal deformity market.
2. The company has disrupted the scoliosis market, offering products that are less invasive and more convenient.
3. In 2015, K2M received 15 FDA approvals and launched numerous new products including Cascade, Everest, Mesa 2 and Capri corpectomy cages.
4. Although the company’s shares seem undervalued, K2M is small and the new products may drive growth in 2016.
More articles on devices:
RTI Surgical launches Streamline TL Spinal Fixation System with new capabilities — 4 highlights
Bodycad introduces Bodycad OnCall for personalized restoration evaluation process — 5 takeaways
Emerging medical device companies find help in AcceLinx’s new program — 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
